Will I be prioritised for this treatment after the trial is over? If I've been on inclisiran during the trial, will I be able to continue the drug after the trial ends?
The trial team at Oxford does not control the availability of the drug in routine care. However, the findings from this study will provide important information for the NHS, and local and national policymakers, to help decide how widely this drug should be made available. If the results of ORION-4 show that inclisiran helps to protect against heart attacks and strokes, then we hope that it will become widely available for patients.